Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MFNS and oxymetazoline combination for seasonal allergic rhinitis
2014-004924-23Phase 2
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of mometasone and oxymetazoline in seasonal allergic rhinitis (SAR) (5 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in AM/PM NOW TNSS averaged over Days 1 to 15.
02
Drugs
mometasoneoxymetazoline
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2014-004924-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004924-23.